AlzeCure Pharma (ALZCUR) Q3 2024 earnings summary

Executive summary

• Focused on developing small-molecule drugs for CNS diseases, especially Alzheimer's and pain, with three platforms: NeuroRestore, Alzstatin, and Painless.

• Advanced clinical and preclinical progress in Alzheimer's and pain projects, with new data presented at major conferences and in scientific publications.

• Raised SEK 44.6 million through rights and directed share issues to support ongoing R&D and business development.

• Continued strong interest from potential partners and investors, with expanded collaborations and patent grants in key markets.

Financial highlights

• Net sales were SEK 0 thousand for both Q3 and the nine-month period, unchanged from the previous year.

• Q3 loss was SEK -7,447 thousand (vs. -7,655), and nine-month loss was SEK -25,904 thousand (vs. -27,411).

• Earnings per share, basic, were SEK -0.08 for Q3 (vs. -0.12) and SEK -0.35 for the nine months (vs. -0.44).

• Cash and cash equivalents at period end were SEK 39,187 thousand (vs. 37,461).

• Research expenses accounted for 68.2% of operating expenses in Q3 and YTD.

Outlook and guidance

• Preparing for Phase II studies for lead Alzheimer's candidate ACD856 and further clinical trials for pain candidate ACD440.

• Alzstatin platform advancing toward clinical phase, with ACD680 prioritized for further development and longer patent protection.

• Ongoing business development to secure partnerships or out-licensing opportunities.

• Board notes that current cash and equity are insufficient for all planned activities over the next 12 months; financing risk remains high.